EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice

Cardiovascular Research

Volumn 96, Issue 1, 2012, Pages 99-108

  Bessi, Valérie L ^a   Labbé, Sébastien M ^b   Huynh, David N ^a   Ménard, Liliane ^a   Jossart, Christian ^a   Febbraio, Maria ^c   Guérin, Brigitte ^b   Bentourkia, M'Hamed ^b   Lecomte, Roger ^b   Carpentier, André C ^b   Ong, Huy ^a   Marleau, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

AMPK; CD36; Micro PET; Myocardial I R

Indexed keywords

ADENYLATE KINASE; CARDIOVASCULAR AGENT; CATECHOLAMINE; CD36 ANTIGEN; EP 51389; EP 80317; FATTY ACID; HORMONE; INSULIN; PALMITIC ACID C 14; PALMITIC ACID DERIVATIVE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; GENETIC ANALYSIS; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART PROTECTION; HEART STROKE VOLUME; INSULIN BLOOD LEVEL; LIPOLYSIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD36; CARDIOTONIC AGENTS; DRUG EVALUATION, PRECLINICAL; ENERGY METABOLISM; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; FLUORODEOXYGLUCOSE F18; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-AKT; RADIOPHARMACEUTICALS; VENTRICULAR FUNCTION, LEFT;

EID: 84866685703     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs225     Document Type: Article

References (41)

1. Chabowski A, Gorski J, Glatz JF, Luiken JJP, Bonen A. Protein-mediated fatty acid uptake in the heart. Curr Cardiol Rev 2008;4:12-21.
2. Smith J, Su X, El-Maghrabi R, Stahl PD, Abumrad NA. Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem 2008; 283:13578-13585.
3. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED et al. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 2007;116:2139-2147.
4. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007;100:1208-1217.
5. De Gennaro Colonna V, Rossoni G, Bernareggi M, Müller EE, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharamacol 1997;334:201-207.
6. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999;140:4024-4031.
7. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000;141:60-66.
8. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002;90:844-849.
9. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 2005;19:1869-1871.
10. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng WL, Pearce SFA et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999;274:19055-19062.
11. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 2004;16:349-360.
12. Bohl S, Medway DJ, Schulz-Menger J, Schneider JE, Neubauer S, Lygate CA. Refined approach for quantification of in vivo ischemia-reperfusion injury in the mouse heart. Am J Physiol Heart Circ Physiol 2009;297:H2054-H2058.
13. Chua CC, Gao J, Ho YS, Xu X, Kuo IC, Chua KY et al. Over-expression of a modified bifunctional apoptosis regulator protects against cardiac injury and doxorubicininduced cardiotoxicity in transgenic mice. Cardiovasc Res 2009;81:20-27.
14. Lecomte R, Cadorette J, Rodrigue S, Lapointe D, Rouleau D, Bentourkia M et al. Initial results from the Sherbrooke avalanche photodiode positron tomograph. IEEE Trans Nucl Sci 1996;43:1952-1957.
15. Ménard SL, Croteau E, Sarrhini O, Gelinas R, Brassard P, Ouellet R et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010;298:E1049-E1057.
16. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001;50:1158-1165.
17. Harb D, Bujold K, Febbraio M, Sirois MG, Ong H, Marleau S. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc Res 2009;83:42-51.
18. Ci X, Frisch F, Lavoie F, Germain P, Lecomte R, van Lier JE et al. The effect of insulin on the intracellular distribution of 14(R,S)-[18F]Fluoro-6- thia-heptadecanoic acid in rats. Mol Imaging Biol 2006;8:237-244.
19. Sorensen J, Valind S, Andersson LG. Simultaneous quantification of myocardial perfusion, oxidative metabolism, cardiac efficiency and pump function at rest and during supine bicycle exercise using 1-11C-acetate PET-A pilot study. Clin Physiol Funct Imaging 2010;30:279-284.
20. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009;2:re3.
21. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001;89:168-173.
22. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
23. Hendrickson SC, St Louis JD, Lowe JE, Abdel-Aleem S. Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol Cell Biochem 1997;166:85-94.
24. Lazar HL. Alterations in myocardial metabolism in the diabetic myocardium. Semin Thorac Cardiovasc Surg 2006;18:289-292.
25. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207-258.
26. Barr RL, Lopaschuk GD. Methodology for measuring in vitro/ex vivo cardiac energy metabolism. J Pharmacol Toxicol Methods 2000;43:141-152.
27. Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of lipolysis in adipocytes. Annu Rev Nutr 2007;27:79-101.
28. Franckhauser S, Munoz S, Pujol A, Casellas A, Riu E, Otaegui P et al. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance. Diabetes 2002;51:624-630.
29. Schwenk RW, Dirkx E, CoumansWA, Bonen A, Klip A, Glatz JF et al. Requirement for distinct vesicle-associated membrane proteins in insulin-and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia 2010;53:2209-2219.
30. Jessen N, Koh HJ, Folmes CD, Wagg C, Fujii N, Lofgren B et al. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta 2010;1802:593-600.
31. Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495-503.
32. Hopkins TA, Dyck JRB, Lopaschuk GD. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans 2003;31:207-212.
33. Crozier SJ, Zhang X,Wang J, Cheung J, Kimball SR, Jefferson LS. Activation of signaling pathways and regulatory mechanisms of mRNA translation following myocardial ischemia-reperfusion. J Appl Physiol 2006;101:576-582.
34. Liem DA, Honda HM, Zhang J, Woo D, Ping P. Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol 2007;103: 2129-2136.
35. Taegtmeyer H. Glycogen in the heart-an expanded view. J Mol Cell Cardiol 2004;37: 7-10.
36. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006;38: 414-419.
37. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
38. Horie T, Ono K, Nagao K, Nishi H, Kinoshita M, Kawamura T et al. Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes. J Cell Physiol 2008;215:733-742.
39. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006;290:H2472-H2479.
40. Oliver MF. Antilipolytic drugs for the prevention of primary ventricular fibrillation. Diabetes Obes Metab 2001;3:61-65.
41. Venturini A, Ascione R, Lin H, Polesel E, Angelini GD, Suleiman MS. The importance of myocardial amino acids during ischemia and reperfusion in dilated left ventricle of patients with degenerative mitral valve disease. Mol Cell Biochem 2009;330:63-70.